The Journal of Heart and Lung Transplantation This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

ECMO as a Bridge to Thoracic Multi-Organ Transplantation
This study aims to investigate temporal trends, utilization, and outcomes in ECMO as a bridge to thoracic multi-organ transplantation. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , A. Krishnan, S. Elde, A. Garrison, M. Fawad, C. Ruaengsri, Y. Shudo, B.A. Guenthart, J. Woo, J.W. MacArthur Source Type: research

A Newly Produced Polymerized Bovine Hemoglobin and Hemoglobin-Based Heart Preservation Solution Prolonged Preservation Duration of Donor Heart in Cold Static Storage and Reduced Myocardial Injury After Allograft Transplantation
This study aimed to develop a heart cardioplegia and preservation solution based on polymerized bovine hemoglobin (HBOC) and assess its potential to enhance cardiac function, extend storage duration, and mitigate ischemia/reperfusion (I/R) injury. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , X. Wang, C. Niu, J. Ji, X. Pan, P. Zhou, S. Zheng Source Type: research

12-Hour Hypothermic Heart Preservation in a Pig Model
Purpose: Extending the heart preservation time using ex situ heart perfusion (ESHP) has been proposed as an optimal method to preserve donated hearts before transplantation. Hypothermic perfusion is a simple method from a device design perspective, and also has enhanced safety compared to normothermic perfusion in the event of device failure. However, the optimal temperature has yet to be determined. We sought to evaluate the effectiveness of 12-hour hypothermic machine perfusion using Belzer Machine Perfusion Solution (MPS) compared to cold static storage (CSS) for 6h followed by simulated transplantation. (Source: The Jo...
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M.J. Wagner, S. Hatami, P. Hassanzadeh, X. Wang, J. Nagendran, D. Freed Source Type: research

Utilizing All the Tools in the ‘Box’ for Heart Transplantation
Purpose: The TransMedics OCS (Andover, MA, USA) normothermic machine perfusion (NMP) device has facilitated the procurement of donation after circulatory death (DCD) donor hearts, as well as marginal brain dead donor (BDD) hearts in our unit since 2014. The XVIVO Heart Box (Gothenburg, Sweden) hypothermic machine perfusion (HMP) was introduced to our unit in 2021 with the aim of overcoming prolonged BDD donor ischemic times (DIT). Australia is a geographically dispersed country and the use of machine perfusion enabled distant procurement. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , J. Villanueva, S. Emmanuel, D. Cornelius, S. Scheuer, C. Soto, J. Cropper, A. Dinale, D. Kaye, D. McGiffin, A. Iyer, A. Watson, M. Connellan, E. Granger, P. Jansz Source Type: research

Outcomes of DCD Heart Transplant: NRP and OCS
Purpose: Donation after cardiac death (DCD) is an effective method to expand the heart transplant donor pool. Multiple methods of procurement exist, including normothermic regional perfusion followed by cold storage (NRP) and direct procurement followed by ex-vivo perfusion with the Transmedics Organ Care System (OCS). This project aims to evaluate outcomes between NRP and OCS transplants and how both compare to donation after brain death (DBD). (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , G.B. Gardner, M. Ambrosio, I. Tchoukina, K. Shah, J. Chery, V. Kasirajan, Z. Hashmi Source Type: research

Prolonged Warm Ischemia and Cold Storage Promote Myocardial Edema in Human Hearts Donated After Circulatory Death via Accumulation of Cyclic Guanosine Monophosphate and Aquaporin 1
Purpose: Significant myocardium edema (ME) is often noted in human hearts donated after circulatory death (DCD), which might contribute to graft dysfunction. The underlying mechanism of ME in DCD hearts was poorly understood. Since activation of cyclic guanosine monophosphate (cGMP) and aquaporin 1 (AQP1) is known to play an important role in tissue edema formation, we measured AQP1, cGMP, and ME in DCD hearts to see if they were correlated, especially with different warm ischemia time (WIT) and subsequent cold storage time(CST). (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , S. Li, K.V. Nordick, A.E. Elsenousi, R. Bhattacharya, R.P. Kirby, A. Mattar, C. Hochman-Mendez, T.K. Rosengart, K.K. Liao Source Type: research

Banff Human Organ Transplant Panel for Detecting Antibody-Mediated Rejection in Lung Transplant Biopsies
Purpose: Diagnosing pulmonary antibody-mediated rejection (AMR) is challenging despite a consensus on its definition. Following prior molecular studies refining rejection diagnostics in other solid organ transplants, we aimed to identify the molecular signature and capture the key functional pathways involved in pulmonary AMR using the Banff Human Organ Transplant (B-HOT) panel. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , N. Belousova, F. Mezine, J. Dagobert, M. Raynaud, P. Bruneval, O. Aubert, C. Lefaucheur, A. Loupy, A. Roux Source Type: research

Distinct Non-HLA Antibody Signatures Correlate with Endothelial Crossmatch Status and Lung Function Decline in Lung Transplant Recipients
Purpose: Non-HLA antibodies against heterogenous targets on endothelial cells have been associated with allograft injury in kidney, heart and lung transplant recipients. The endothelial-Cell Cross match (ECXM) is used in detection of non-HLA antibodies but remains non-discriminatory for specific antibody identification. The primary objective of this study was to delineate the specific non-HLA antibody signatures associated with EC positivity and to determine the temporal effect of EC status and non-HLA antibody signatures on allograft health. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , F. Alhamdan, A. Coppolino, A. Sheikh, N. Sharma Source Type: research

A Serum Autoantibody (AAB) Signature is Associated with Future CLAD
Purpose: AABs have been linked to chronic lung allograft dysfunction (CLAD), but whether combinations of lung- and ubiquitously-targeted AABs can better predict CLAD has been underexamined. We aimed to investigate this supposition in a single-centre cohort. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , A. Ulahannan, A. Chruscinski, P. Lombardi, J. Semenchuk, T. Martinu, S. Juvet Source Type: research

A Molecular Criteria for Antibody Mediated Rejection in Lung Transplant Recipients is Associated with an Increased Risk of the Composite Outcome of CLAD and Death
Purpose: Pulmonary antibody mediated rejection (AMR) is associated with chronic lung allograft dysfunction (CLAD) and death. The current International Society for Heart and Lung Transplantation (ISHLT) criteria for AMR is predicated on a constellation of clinical, laboratory and histopathological parameters, including the presence of donor-specific antibodies (DSA). The degree of allograft injury on the molecular level, as measured by donor-derived cell-free DNA (dd-cfDNA), is not considered in the ISHLT criteria but may identify patients experiencing a form of antibody mediated rejection. (Source: The Journal of Heart and...
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M. Alnababteh, L. Ponor, P. Shah, J. Mathew, R. Bower, H. Kong, T. Andargie, W. Park, A. Charya, T. Intrieri, H. Luikart, S. Aryal, S. Nathan, J. Orens, K. Khush, M. Jang, S. Agbor-Enoh Source Type: research

Transient versus Persistent Donor Specific Antibodies and Outcomes After Lung Transplantation
Purpose: De novo donor-specific antibodies (dnDSAs) and antibody-mediated rejection (AMR) have gained significant interest over the last years. However, little is known about the clinical significance of transient versus persistent dnDSAs and their impact on patient outcomes and graft survival. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , C. Hillebrand, P.M. Boehm, J. Boecker, D. Koren, S. Schwarz, Z. Kovacs, G. Murakoezy, E. Hielle-Wittmann, G. Fischer, C. Aigner, K. Hoetzenecker, P. Jaksch, A. Benazzo Source Type: research

Pre-Transplant T Lymphocyte Mycophenolic Acid Resistance is Associated with Aberrant Cytokine Production and Acute Rejection Among Lung Transplant Recipients
Purpose: Mycophenolic acid (MPA), the anti-proliferative immunosuppression agent of choice for lung transplant recipients, demonstrates extensive response variability. We assessed pre-transplant MPA sensitivity influence on T lymphocyte function and post-transplant outcomes in lung transplant recipients. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , R. Ebenezer, H. Anthony, R. Hachem, A. Gelman Source Type: research

Survival in Alpha-1 Antitrypsin (A1AT) Deficient Lung Transplant Recipients by Use of A1AT Augmentation Therapy
Purpose: While Lung Transplant (LT) is a key treatment for patients with Alpha-1 Antitrypsin Deficiency (A1ATD), there is currently insufficient evidence to determine whether these recipients should receive A1AT augmentation therapy post-LT. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , J. Ruck, A. Casillan, R. Riojas, P. Shah, J. Ha, S. Strout, A. Massie, D. Segev, C. Merlo, E. Bush Source Type: research

CD38 Antibody Daratumumab as an Add-On Rescue Therapy for AMR - First Report in Clinical Lung Transplantation
Purpose: Antibody-mediated rejection (AMR) following lung transplantation (LTx) poses a major threat to allograft function. Current treatments focus on depleting circulating antibodies and suppressing B-cell activity, but often fail to reduce donor-specific antibodies (DSAs) adequately. Daratumumab, a monoclonal antibody that targets CD38 and depletes plasma cells and NK cells, could potentially improve AMR outcomes. Herein, we report the first use of daratumumab in the setting of lung transplantation. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , S. Auner, D. Koren, G. Fischer, Z. Kovacs, P.M. Boehm, C. Aigner, K. Hoetzenecker, F. Calabrese, P. Jaksch, A. Benazzo Source Type: research

The Multicenter KOALA Study: The Effects of Kaftrio After Lung Transplantation in Cystic Fibrosis
Purpose: Historically, the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator Kaftrio has been withheld from lung transplant (LTx) recipients with Cystic Fibrosis (CF) due to uncertainty regarding its efficacy, concerns about potential drug interactions and costs. The focus of Kaftrio therapy has been on pulmonary improvement instead of extrapulmonary benefits. However, considering the multi-systemic nature of CF, and the persistence of extrapulmonary symptoms after LTx, Kaftrio may also have potential relevant benefits for CF patients post-transplant. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , B. Luijk, M. Hellemons, K.A. Visser, C.M. Hansen, R. van der Meer, T. Gan, H. van der Vaart, O. Akkerman, W.N. Steenhuis, H.G. Heijerman, E.A. Verschuuren Source Type: research